Table 1b. Further studies found by the updating process.

Study	Indications, design, and methods	Results and conclusions	Do the findings support the conclusion?	EL	Conflict of interest?
Tanikawa 2013 (26)	Prospective, two-armed, randomized, blinded trial; CAL vs. AFT in 18 patients with craniofacial microsomia Method: CT volumetry Follow-up: Up to 12 months	Significantly better volume retention in the CAL group; 4 dropouts (2 per group); CAL is safe, effective, and superior to AFT	High methodological quality; sole study known to us showing an advantage for CAL for a special indication. Conclusion about safety not supported by findings. Limitations: low number of patients, high dropout rate, not generalizable to common indications	II–III	No financial conflict of inerest
Perez-Cano 2012 (11)	Prospective, one-armed, multicenter trial: CAL in 71 women after breast-conserving treatmentMethods: Clinical examination, LENT-SOMA, assessment of pt. satisfaction on a 6-point scale, MRI Follow-up: Up to 12 Monate	4 dropouts, repeat procedures in 24 pts., MRI abandoned for inadequate sensitivity; pts. and physicians generally satisfied; bone metastasis (1 pt.), cyst formation (10 pts.);CAL is safe and effective	Conclusion not at all supported by findings; marked methodological deficiencies	IV	Technical and financial support of the device manufacturer
Peltoniemi 2013 (27)	Prospective, two-armed, non-randomized trial; 18 patients underwent CAL or AFT for breast augmentation Method: MRI volumetry Follow-up: Up to 6 months	No significant intergroup difference; one case of cyst formation in each group; trial terminated because of lack of advantage from CAL; AFT quicker, cheaper, and theoretically safer with at least equivalent outcomes	The conclusion is reasonable, although the trial groups were small	III	No conflict of interest

AFT, autologous fat transfer; CAL, cell-assisted lipotransfer; EL, evidence level; LENT-SOMA, late effects on normal tissues, subjective/objective management analysis (interdisciplinary assessment of long-term oncologic treatment outcomes); MSC, mesenchymal stem cells; pt./pts., patient(s)